Two-Drug combo tested to keep relapsed blood cancer at bay
NCT ID NCT03622775
Summary
This study tested whether a two-drug maintenance therapy could help control multiple myeloma that has returned after a patient's second stem cell transplant. The treatment combined an antibody drug (daratumumab) with a chemotherapy pill (pomalidomide), given for up to three years. The goal was to see if this approach could achieve deep remissions and delay the cancer's progression in a small group of 13 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.